The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces diverse extracellular signals to protein networks that control proliferation, survival, migration, and …

May 23, 2024 · The BCR::ABL1-positive subtype and ABL-class subtype, each accounting for ∼3% of newly diagnosed pediatric ALL cases, involve fusions with ABL family tyrosine kinase …

Jan 28, 2015 · Mutations in the ABL kinase domain and SH3-SH2 domain of the BCR/ABL gene and amplification of the Philadelphia chromosome are the two important BCR/ABL dependent …

Mar 14, 2024 · In this article, we systemically review the structural and molecular properties of the critical domains of BCR::ABL1 and how understanding the essential role of BCR::ABL1 kinase …

In this study, we present a novel DNA-based next-generation sequencing (NGS) methodology for KD ABL1 mutation detection and monitoring with a 1.0E−4 sensitivity. This approach was …

Nov 22, 2020 · ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, …

ABL1 K357dup indicates the insertion of the duplicate amino acid, lysine (K)-357, in the protein kinase domain of the Abl1 protein (UniProt.org).

Introduction: The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these …

Sep 14, 2010 · ABL1 includes nuclear localization signals and a DNA bind-ing domain through which it mediates DNA damage-repair functions, whereas ABL2 has additional binding …

Jun 25, 2024 · Four BCR–ABL1 tyrosine-kinase inhibitors (TKIs) are approved for patients with newly diagnosed chronic myeloid leukaemia (CML): the first-generation agent imatinib and …